Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 160

Similar articles for PubMed (Select 16478879)

1.

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG.

Blood. 2006 Jun 1;107(11):4274-81. Epub 2006 Feb 14.

2.

Corrigendum to "Combination therapy with interferon and JAK1-2 inhibitor is feasible. Proof of concept with rapid reduction in JAK2V617F-allele burden in Polycythemia Vera" [Leuk. Res. Rep. 3 (2) (2014) 73-75].

Bjørn ME, de Stricker K, Kjær L, Ellemann K, Hasselbalch HC.

Leuk Res Rep. 2015 May 15;4(1):31. doi: 10.1016/j.lrr.2015.04.003. eCollection 2015.

3.

Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice.

Yan D, Jobe F, Hutchison RE, Mohi G.

Leukemia. 2015 May 18. doi: 10.1038/leu.2015.116. [Epub ahead of print]

PMID:
26044284
4.

Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells.

Lu M, Xia L, Liu YC, Hochman T, Bizzari L, Aruch D, Lew J, Weinberg R, Goldberg JD, Hoffman R.

Blood. 2015 May 28. pii: blood-2014-12-618595. [Epub ahead of print]

PMID:
26022238
5.

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

Pieri L, Pancrazzi A, Pacilli A, Rabuzzi C, Rotunno G, Fanelli T, Guglielmelli P, Fjerza R, Paoli C, Verstovsek S, Vannucchi AM.

Blood. 2015 May 21;125(21):3352-3. doi: 10.1182/blood-2015-01-624536. No abstract available.

PMID:
25999444
6.

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.

Yönal I, Dağlar Aday A, Akadam Teker B, Ceylan Y, Nalcacı M, Yavuz AS, Sargın FD.

Turk J Haematol. 2015 Apr 27. doi: 10.4274/tjh.2014.0136. [Epub ahead of print]

PMID:
25913509
7.

Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: a single center experience.

Singh N, Sazawal S, Upadhyay A, Chhikara S, Mahapatra M, Saxena R.

Indian J Pathol Microbiol. 2015 Apr-Jun;58(2):187-91. doi: 10.4103/0377-4929.155311.

8.

Lu/BCAM-mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients.

De Grandis M, Cassinat B, Kiladjian JJ, Chomienne C, El Nemer W.

Am J Hematol. 2015 Jul;90(7):E137-8. doi: 10.1002/ajh.24023. Epub 2015 May 28. No abstract available.

PMID:
25809027
9.

Translocation t(3;12)(q26;q21) in JAK2(V617F) Point Mutation Negative Chronic Idiopathic Myelofibrosis: A Case Report.

Mešanović S, Šahović H, Perić M.

Balkan J Med Genet. 2014 Dec 11;17(1):63-8. doi: 10.2478/bjmg-2014-0026. eCollection 2014 Jun.

10.

CD133 marks a stem cell population that drives human primary myelofibrosis.

Triviai I, Stübig T, Niebuhr B, Hussein K, Tsiftsoglou A, Fehse B, Stocking C, Kröger N.

Haematologica. 2015 Jun;100(6):768-79. doi: 10.3324/haematol.2014.118463. Epub 2015 Feb 27.

11.

BCR-JAK2 drives a myeloproliferative neoplasm in transplanted mice.

Cuesta-Domínguez Á, León-Rico D, Álvarez L, Díez B, Bodega-Mayor I, Baños R, Martín-Rey MÁ, Santos-Roncero M, Gaspar ML, Martín-Acosta P, Almarza E, Bueren JA, Río P, Fernández-Ruiz E.

J Pathol. 2015 Jun;236(2):219-28. doi: 10.1002/path.4513. Epub 2015 Mar 3.

PMID:
25664618
12.

JAK2V617F mutation and endogenous erythroid colony formation in patients with polycythaemia vera.

Strnad M, Todoric Zivanovic B, Tatomirovic Z, Tarabar O, Elez M, Radic O, Stamatovic D.

J BUON. 2014 Oct-Dec;19(4):985-91.

PMID:
25536606
13.

Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.

Shirane S, Araki M, Morishita S, Edahiro Y, Sunami Y, Hironaka Y, Noguchi M, Koike M, Sato E, Ohsaka A, Komatsu N.

Int J Hematol. 2015 Feb;101(2):148-53. doi: 10.1007/s12185-014-1721-9. Epub 2014 Dec 19.

PMID:
25522845
14.

Nongenetic stochastic expansion of JAK2V617F-homozygous subclones in polycythemia vera?

Godfrey AL, Nangalia J, Baxter EJ, Massie CE, Kent DG, Papaemmanuil E, Campbell PJ, Green AR.

Blood. 2014 Nov 20;124(22):3332-4. doi: 10.1182/blood-2014-09-603043. No abstract available.

15.

Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.

Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Taniguchi Y, Hidaka T, Kubuki Y, Shimoda H, Marutsuka K, Sashida G, Aoyama K, Yoshimitsu M, Harada T, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Iwama A, Kitanaka A, Shimoda K.

Blood. 2015 Jan 8;125(2):304-15. doi: 10.1182/blood-2014-04-555508. Epub 2014 Nov 13.

PMID:
25395421
16.

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera.

Bjørn ME, de Stricker K, Kjær L, Ellemann K, Hasselbalch HC.

Leuk Res Rep. 2014 Aug 1;3(2):73-5. doi: 10.1016/j.lrr.2014.05.003. eCollection 2014. Erratum in: Leuk Res Rep. 2015;4(1):31.

17.

Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.

Barosi G.

Best Pract Res Clin Haematol. 2014 Jun;27(2):129-40. doi: 10.1016/j.beha.2014.07.004. Epub 2014 Jul 18.

PMID:
25189724
18.

p53 at the crossroads of MPN treatment.

Plo I.

Blood. 2014 Jul 31;124(5):668-9. doi: 10.1182/blood-2014-06-579623.

19.

Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.

Angona A, Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, Camacho L, Fernández-Rodríguez C, Pairet S, Longarón R, Ancochea Á, Senín A, Florensa L, Besses C.

Eur J Haematol. 2015 Mar;94(3):251-7. doi: 10.1111/ejh.12425. Epub 2014 Sep 13.

PMID:
25082530
20.

Generation and characterization of a JAK2V617F-containing erythroleukemia cell line.

Zhao W, Zou K, Farasyn T, Ho WT, Zhao ZJ.

PLoS One. 2014 Jul 18;9(7):e99017. doi: 10.1371/journal.pone.0099017. eCollection 2014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk